Based on a randomized clinical trial, Idelalisib in combination with rituximab appeared to benefit pre-treated patients with CLL and showed equivalent activity in patients with and without abnormalities of the TP53 pathway (83). The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.